Navigation Links
Novation Applauds New FDA Guidance Documents on Biosimilars

IRVING, Texas, Feb. 15, 2012 /PRNewswire/ -- The publication of three guidance documents by the Food and Drug Administration represents a significant milestone in the biosimilar development process and provides the infrastructure by which pharmaceutical manufacturers can seek approval for lower cost, clinically comparable alternatives to some of the most commonly utilized biologic agents purchased by health care organizations.     

Novation, the health care industry's leading supply contracting company for the members and affiliates of VHA Inc, UHC and Provista, has been actively monitoring the development process for biosimilars, improving its understanding of how biosimilars have progressed in Europe and identifying the keys issues members will have to address when considering how to use biosimilars.    

In recent years, an increasing amount of hospital pharmaceutical expense is being devoted to the acquisition of high cost, large molecule biologics, which historically have not been subject to "generic" competition because they are complex to manufacture and are derived from living organisms.  Biosimilars, or drugs that clinical studies deem "highly similar" to these large molecule biologics, will provide effective, safe, and cost-efficient alternatives to expensive, current biologic drugs.  

Based upon the experience in the European biosimilars market, these "highly similar" versions of reference biologics could result in price decreases of 20% to 30%.  "However, adoption of biosimilars will be a more complex process and will require greater physician involvement in contrast to what traditionally happens with small molecule generics," said Steven Lucio, director of pharmacy clinical solutions for Novation.  "Health care organizations will have to devote more resources to the evaluation of these products. Therefore, it is critically important for Novation to provide the tools and resources needed to conduct this evaluation and educate prescribers and other clinicians." 

Novation offers multiple clinical resources to the members it serves including the Drug Monograph Service and the biannual Drug Price Forecast.  Both of these tools will be expanded to reference the availability of biosimilars. Novation recently initiated the process of educating its member organizations on biosimilars with the publication of its white paper titled, "Preparing for Biosimilars." To view this white paper, please view:   


About Novation, Winner of the Ethics Inside® Certification
Founded in 1998, Novation is the leading health care supply contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase more than $40 billion in 2011. Novation recently earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance, and is the only health care group purchasing organization to earn this distinction.


SOURCE Novation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Year
2. Innovation Day 2012: a Time To Inform and Inspire
3. BioParadox Announces Partnership with Fogarty Institute for Innovation
4. Celebrity Chef Danny Boome Announces Launch of, A New Online Resource Featuring Smart Solutions And Product Innovations For People With Arthritis
5. DLP® LightCrafter™ From Texas Instruments: Enabling Big Innovations In Light Steering From A Compact, Ready-To-Use Module
6. Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry
7. Innovations in Wound Care Devices and Dressings
8. Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation
9. First Ever InnoPack Event Has Strong Turn Out and a Focus on Innovation
10. Austen BioInnovation Institute and Lubrizol Announce New Strategic Innovation Partnership
11. Mindray Signs Agreement With Novation
Post Your Comments:
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
(Date:12/1/2015)... , Dec. 1, 2015 Breg, Inc ... services, announced today that it has been awarded three ... Members served by Novation will have access to improved ... bracing products and soft goods dedicated to advancing orthopedic ... The aging U.S. population, rising prevalence of chronic ...
(Date:12/1/2015)... , Dec. 1, 2015 Building ... HIV/AIDS, Johnson & Johnson (NYSE: JNJ ) ... Janssen Pharmaceutical Companies to significantly reduce the burden ... make up 74 percent of new HIV infections ... on World AIDS Day, these new initiatives include ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, ... announced that the organization has awarded Education and Developmental Therapies (EDT), an Applied ... The award celebrates exceptional special needs providers that excel in synthesizing the areas ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... , ... December 01, 2015 , ... XTC Semifinals ... 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer ... of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Nurotron Biotechnology ... in its largest order to date. , The order will be from the ... Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults suffering ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes ... and support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact ...
Breaking Medicine News(10 mins):